It is the broad, long-term goal of this program to build on and extend the current knowledge in the field of bone marrow transplantafion and hematological malignancies. This program is a mulfidisciplinary clinical, basic and translational research effort whose overall goal is to improve outcomes for patients with solid and liquid malignancies. To this end, the investigators of this application will ufilize the approach of translational research, bridging the novel experimental concepts and observations made at the laboratory bench to clinical applicafion at the pafients'bedsides. In both basic and clinical areas, the HCTHM Program fosters interacfions between many Programs and members of the DCCI. The Program includes 35 members from 11 basic and clinical departments within Duke University. Total funding for program members is $68,881,117, of which $64,009,143 is from peer- reviewed sources. A cancer focus is illustrated by $976,102 or 1.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004- 2008, program members published 706 papers in peer-reviewed journals cited in PubMed. Of these publicafions, 6.4% are the result of intra-programmatic collaborations and 13% due to inter-programmafic collaborations.
The aims of the Program are: 1. To optimize the use of allogeneic and autologous transplantation of hematopoiefic stem cells. 2. To use and compare various alternative sources of hematopoietic stem cells for allogeneic transplantation. 3. To develop novel preparatory regimens for allogeneic stem cell transplantation. 4. To understand the basic biology of graft versus tumor (GvT) and to explore new ways to induce GvT effects following transplantation. 5. To study the nature of and define the problems associated with hematopoiefic and immunologic reconstitution after allogeneic transplantation with the overall goal of developing novel supportive care measures for patients transplanted with stem cells from alternative and mismatched donors. 6. To understand hematopoietic stem cell development and control of differentiation. 7. To promote effective interactions of the members of the Duke Comprehensive Cancer Institute that will stimulate new translational research efforts to improve the care of patients with hematologic malignancies. 8. To identify new cellular and stromal targets for therapy with antibodies or small molecules, leading to evaluafion of various labeling techniques, such as using radiolabels or diphtheria toxins, of small molecules and antibodies with subsequent clinical evaluation of safety and efficacy. 9. To evaluate the importance of different signaling mechanisms in leukemogenesis or lymphomagenesis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955

Showing the most recent 10 out of 513 publications